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Abstract Parkinson’s disease and dementia with Lewy
bodies are major challenges in research and clinical
medicine world-wide and contribute to the most com-
mon neurodegenerative disorders. Previously, specific
mitochondrial polymorphisms have been found to en-
hance clearance of amyloid-β from the brain of APP-
transgenic mice leading to beneficial clinical outcome. It
has been discussed whether specific mitochondrial alter-
ations contribute to disease progression or even prevent
toxic peptide deposition, as seen in many neurodegener-
ative diseases. Here, we investigated α-synuclein-
transgenic C57BL/6J mice with the A30P mutation,
and a novel A30P C57BL/6J mouse model with three
mitochondrial DNA polymorphisms in the ND3, COX3
and mtRNAArg genes, as found in the inbred NOD/LtJ
mouse strain. We were able to detect that the new mod-
el has increased mitochondrial complex II-respiration
which occurs in parallel to neuronal loss and improved
motor performance, although it exhibits higher amounts
of high molecular weight species of α-synuclein. High
molecular weight aggregates of different peptides are
controversially discussed in the light of neurodegenera-
tion. A favourable hypothesis states that high molecular
weight species are protective and of minor importance
for the pathogenesis of neurodegenerative disorders as
compared to the extreme neurotoxic monomers and olig-
omers. Summarising, our results point to a potentially
protective and beneficial effect of specific mitochondrial
polymorphisms which cause improved mitochondrial
complex II-respiration in α-synucleinopathies, an effect
that could be exploited further for pharmaceutical
interventions.
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Parkinson’s disease is one of the most spread neurological
disorders with motor and cognition deficiencies in the world.
It is characterised by diverse symptoms, including movement
deteriorations, rigidity, bradykinesia, tremor, postural instabil-
ity and also dementia. Morphological findings in the brain of
patients reveal a tremendous loss of dopaminergic neurons in
the substantia nigra pars compacta. Furthermore, distinct
proteinous inclusion bodies (Lewy bodies, Lewy neurites),
which are deposited in brain neurons, are the prominent mor-
phological hallmark [1] (reviewed in [2–4]). These inclusions
are mainly composed of α-synuclein (aSYN), a 14-kDa pep-
tide localised at presynaptic sites in brain neurons, which is
thought to have distinct physiological functions as being im-
plicated in the modulation of synaptic activity, neurotransmit-
ter release and lipid metabolism (reviewed in [5–7]). This
peptide plays also a crucial role in pathology of dementia with
Lewy bodies and other neurodegenerative diseases like
Alzheimer’s disease [8, 9]. Several reports hold the opinion
that higher molecular weight aggregates of aSYN are the toxic
compound in the brain of Parkinson’s patients, while others
denote the monomers and small oligomers to be the crucial
peptide species (reviewed in [4, 10]). Numerous mutations in
SNCA (aSYN gene) causing inherited forms of the disease
have been identified, leading to identical clinical outcome,
but do appear in only 10 % of all Parkinson’s disease cases
[11, 12]. These mutations were often used as basis to generate
mouse models of the disease. One very widespread used mu-
tation of aSYN, first discovered in a German family, is the
autosomal dominant ‘A30P’ missense mutation, in which al-
anine at position 30 is replaced by proline leading to enhanced
fibril formation [13].
Currently, very intensively debated is the mitochondrial
dysfunction, a pathogenicmechanismwhich has been in focus
of research ever since the first description of complex I-
deficiency in the substantia nigra, but also in platelets of
Parkinson’s disease patients [14–16]. Mutations in the mito-
chondrial DNA, which are thought to occur during life and
especially with increasing age, lead to the production of reac-
tive oxygen species, normally regulated by antioxidants
(reviewed in [3]). This process is believed to be disturbed in
old age, respectively, in neurodegenerative diseases (reviewed
in [17]), and leads to further damage in mitochondria and in
pathways for degradation and removal/efflux of aSYN as well
as other peptides [18]. Since then, a number of mutations in
genes for PTEN-induced putative kinase 1 (PINK1),
Parkinson protein 2 (PARK2), Parkinson protein 7 (parkk7/
DJ-1), Leucin-rich repeat kinase 1 (LRRK1) and others have
been shown to induce Parkinson’s disease symptoms, mostly
early onset and indistinguishable from sporadic cases [19, 20]
(reviewed in [21]). At the same time, it could be revealed that
aSYN binds to mitochondria and shifts its fusion and fission
balance towards fission [22]. However, the mechanisms lead-
ing to the onset of Parkinson’s disease are still unknown and
the spatial and temporal sequence of events that trigger pa-
thology remain to be elucidated.
To examine whether the modification of mitochondrial
function influences the aSYN pathology of a widely used
Parkinson’s disease/dementia with Lewy bodies mouse mod-
el, respectively, we generated a novel mouse line as derivative
of the A30P mouse line (tg-aSYN-B6) with specific modifi-
cations in the mitochondrial genome (tg-aSYN-mtNOD). A
related mouse model was previously described in the context
of Alzheimer’s disease by Scheffler et al. [23], who showed
increased production of ATP in NOD/LtJ-derived mitochon-
drial conplastic mice with resulting reduced amyloid-β bur-
den and increased microglial function. We compared both
mouse models (tg-aSYN-B6 and tg-aSYN-mtNOD) with re-
gard to aSYN load in the brain, motor performance and dif-
ferences in microglial response as well as number of cortical
neurons. Additionally, we determined mitochondrial function
of the C57BL/6J background control strains of the generated
lines biochemically by examining the respiration rate of iso-
lated brain mitochondria with and without mitochondrial
polymorphisms (mtNOD and C57BL/6J). Our findings reveal
that the variations in complex II-dependent respiration rates
go along with an improvement in behaviour, e.g. motor per-
formance, and the total number of cortical neurons. We could
show that it is also accompanied by an increase in the aSYN
burden in brains of old transgenic mice, of higher molecular
aggregates of aSYN in particular.
Surprisingly, we detected that an increased microglial re-
sponse with advancing age is lacking contrary to the findings
of Scheffler et al. [23] in Alzheimer’s disease mouse models.
Furthermore, we found that tg-aSYN-B6 mice lack worsening
of motor skills when compared to non-transgenic controls.
Thus, we propose to change the denotation of these mice from
a Parkinson’s disease mouse model to rather being a general
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C57BL/6J mice (controls) were purchased from Jackson
Laboratory (Bar Harbor, ME, USA) and provide the ge-
nomic background of the transgenic mouse strains. Tg-
aSYN(A30P)-B6 mice were obtained from and described
earlier by Kahle et al. [24] and carry the human trans-
gene aSYN with the ‘A30P’ mutation, which is
expressed under the neuron-specific Thy1 promoter
[24]. To generate the mtDNA conplastic strain tg-
aSYN-mtNOD, we used the mouse inbred strain NOD/
LtJ, purchased from Jackson Laboratory which has been
sequenced previously [25]. The method for generation of
a similar mouse strain was already described by Scheffler
et al. [23]. Briefly, female mice of the NOD/LtJ strain
were mated with male C57BL/6J mice for more than ten
generations, always crossing females with C56BL/6J
males. Finally, male tg-aSYN-B6 mice were crossed to
females of the generated mitochondrial conplastic strain
to generate tg-aSYN-mtNOD mice in the genomic
C57BL/6J background.
Mice at an age of 50 and 300 days were used for immuno-
histochemical analyses and ELISA; the behavioural tests were
performed using mice starting at 50 days of age until 300 days
of age.
For respirometry, we used 100 and 200 days old
mice with the specific genomic background, denoted
as C57BL/6J and mtNOD mice, and without transgene
overexpression. All mice were housed in a climate-
controlled environment on a 12-h light/dark cycle with
free access to rodent food and water. All experiments
were conducted in accordance to the EU and state law
of Saxony-Anhalt and approved by the local animal
ethics committee.
Biochemical and Immunohistochemical Analyses
Tissue Preparation
Mice were killed by cervical dislocation and transcardially
perfused with phosphate-buffered saline (pH 7.4). One brain
hemisphere was transferred into 4 % paraformaldehyde for at
least 48 h and finally stored in PBS while the second hemi-
sphere was snap-frozen in liquid nitrogen and stored at
−80 °C.
Isolation of Mitochondria
For functional analyses, mouse brain mitochondria from 100-
and 200-day-old mice were isolated as described by Gellerich
et al. [26] using a modified protocol according to Clark and
Nicklas [27]. For that, one brain hemisphere was transferred
into ice-cold MSE-A (225 mM mannitol, 75 mM sucrose,
20 mM MOPS, 1 mM EGTA, 0.5 mM DTT, ddH2O,
pH 7.4) containing 0.05 % nagarse and homogenised with a
glass homogeniser. The homogenates were diluted 1:4 with
MSE-A, and centrifuged at 2000×g for 4 min. Afterwards, the
supernatant was filtered and centrifuged again at 12,000×g for
10 min. The pellet containing the mitochondria was re-
suspended in 5 ml MSE-A containing 0.02 % digitonin, and
after an additional centrifugation step in 20 ml MSE-A at 12,
000×g for 10 min, the pellet was re-suspended in 100 μl
MSE-B (225 mM mannitol, 75 mM sucrose, 20 mM MOPS,
0.1 mM EGTA, 0.5 mM DTT, ddH2O, pH 7.4). Protein con-
centration was determined using the Bicinchoninic Acid Kit
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and the
SunriseTM Reader (Tecan Deutschland GmbH, Crailsheim,
Germany).
Respirometry
Respirometry was performed using OROBOROS oxygraph-
2k (Oroboros Instruments, Innsbruck, Austria) equipped with
Clark-type oxygen electrodes. Respiration of mitochondria
(0.06 mg protein/ml) was measured at 30 °C in a medium
(BIM-1000) containing 120 mM mannitol, 40 mM MOPS,
5 mMKH2PO4, 60 mMKCl, 5 mMMgCl2 and 1 mMEGTA,
pH 7.4. Fluorimetrically measured Ca2+ concentration in this
medium (Ca2+cyt) was 11 nM. To study the substrate specific
as well as the respiratory chain complex-dependent rates of
state 3 (maximum) respiration, four different protocols were
used (see Supplementary Materials Table 1). As shown in
Fig. 1 and in Supplementary Material, protocols I (and II)
were started under conditions of very low Ca2+ (11 nM). For
that, mitochondria were incubated in a 1 mM EGTA-contain-
ing BIM-1000 medium. In the presence of 10 mM glutamate
and 2 mM malate (protocol I), the addition of 2 mM ADP
adjusted the maximum possible respiration with these sub-
strates (state 3glu/mal), which was stimulated by two subse-
quent Ca2+ additions. This procedure allowed testing the acti-
vation of mitochondrial substrate supply by extra-
mitochondrial Ca2+ [28]. After addition of 10 mM pyruvate,
the complex I-dependent state 3com.I was reached. Afterwards,
1.5 μM rotenone, an inhibitor of complex I fully repressed the
complex I-dependent respiration. The following addition of
10 mM glycerol-3-phosphate adjusted the state 3G3P, whereas
the state 3suc followed succinate addition (complex II). Now
antimycin A, an inhibitor of complex III, fully withdrew the
oxidation of these both substrates. Finally, ascorbate/TMPD
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allowed measuring the maximum oxidation rate of reduced
cytochrome c by cytochrome c oxidase. To correct this rate
by unspecific oxygen consumption, azide (inhibitor of cyto-
chrome c oxidase) was applied. In protocol II, 10 mM α-
ketoglutarate was used in the second incubation step, instead
of 10 mM glutamate. Protocols III and IV were performed in
the absence of EGTA allowing a larger endogenous Ca2+ con-
tent, sufficient to fully activate the Ca2+ stimulated substrate
supply. Starting with pyruvate/malate, at first a small amount
of ADP was added to adjust a partially activated state of res-
piration. After a short time, the rate of respiration decreased
again (state 4). Then, 2 mMADP was added to reach the state
3pyr/mal. In the next step, addition of 10 mM glutamate led to
state 3com.I and the further addition of succinate adjusted the
state 3com.III. To check a possible limitation of the oxidative
phosphorylation (OXPHOS) by a dysfunctional ATPase, we
performed a stepwise FCCP addition causing an increasing
uncoupling of OXPHOS. Protocol IV started with adding
10 mM glutamate and 2 mM malate and reaching state 4glu/
mal and state 3glu/mal, before 10 mM pyruvate then adjusted
state 3com.I. After the application of 10 mM succinate, state
3com.III was measured. This is due to the fact that the sum of
state 3com I plus state 3com II is generally higher that state 3com
III. Therefore, the complex III is rate limiting under these con-
ditions. Rotenone inhibited the complex I-dependent respira-
tion allowing the registration of state 3suc. Finally, 125 μM
atractyloside allowed the measurement of state 4atractyloside.
These protocols enabled the examination of maximum oxida-
tion rates of all used substrates and the maximum flux rates of
respiratory chain complexes I, II, III, IV and V. Moreover,
several ratios and special properties, e.g. respiratory control
ratio (RCR) and non-phosphorylating (state 4) respiration,
were analysed. The oxygen concentration in air-saturated me-
dium was considered to be 200 nmol O2/ml at 95 kPa. Mito-
chondrial protein-related oxygen consumption was calculated
from the time derivative of oxygen concentration (Datagraph
Analysis software, Oroboros Instruments, Austria). Data are
given in nanomole O2/minute/milligram mitochondrial
protein.
Enzyme-Linked Immunosorbent Assays
For quantitative analysis, we used ELISA kits (AJ Roboscreen
GmbH, Leipzig, Germany) to detect monomeric but also
Fig. 1 Representative
respirograms of 200-day-old
C57BL/6J (a) and mtNOD mice
(b). Shown is the sequential
addition of substrate according to
the first experimental approach
‘protocol I’ (see Table 1 in
Supplementary Materials) and the
resulting changes in O2
concentration (black line) and O2
flux (grey line), which were
further evaluated. The addition of
mitochondria to the medium
results in an immediate increase
in oxygen consumption (first peak
in A and B marked with asterisk)
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higher molecular forms of aSYN (MONO kit). Therefore,
snap-frozen mice brain were gently thawed at 4 °C and
homogenised (SpeedMILL PLUS, Analytik Jena AG, Germa-
ny) once for 30 s before transferred into 20 volumes (w/v)
carbonate buffer (100 mM Na2CO3, 50 mM NaCl, ddH2O,
pH 11.5) and homogenised again for 20 s. After centrifugation
at 18,500×g for 20 min, the supernatant was captured and
denoted carbonate fraction. The remaining pellet of the car-
bonate fraction was used to produce the guanidine fraction by
adding 8 volumes (w/v) 5 M guanidine hydrochloride buffer
(5 M Guanidin/HCl, 50 mM Tris/HCl, ddH2O, pH 8) to the
initial tissue weight and mixing gently at room temperature for
3 h before centrifuging again. The supernatant was collected
as guanidine fraction. The ELISAwas performed according to
the manufacturer’s instructions. The bound HRP-coupled an-
tibody complex was visualised by TMB/H2O2 staining and
absorption measured using a PARADIGM spectrophotometer
(Beckman-Coulter/Molecular Devices, Germany). Protein
content was determined by spectrophotometric measurements
(ScanDrop, Analytic Jena AG, Germany).
Immunohistochemistry
For immunohistochemistry, paraformaldehyde-fixed brain
hemispheres were dehydrated, paraffin-embedded and cut into
4 μm-thick coronal sections as previously published [23,
29–31]. After de-paraffinisation and re-hydration, immuno-
staining was performed using the BOND-MAX Autostainer
(Leica Microsystems GmbH/Menarini, Germany). Therefore,
endogenous peroxidase was blocked (5 min) and epitopes
retrieved for 5 min with citrate (for anti-human aSYN (clone
5G4, AJ Roboscreen), anti-neuronal nuclei (NeuN,
Chemicon/Millipore), EDTA buffer pH 8.5 (for Iba1, WAKO)
or enzymatic (for glial fibrillary acidic protein [GFAP],
DAKO). Antibodies were incubated for 30 min with follow-
ing dilutions: aSYN 5G4 (1:6000), NeuN (1:500), Iba1
(1:1000) and GFAP (1:500), and detected with BOND-
MAX Bond Polymer Refine Detection kit (DAB R30). Addi-
tionally, sections were counterstained with haematoxylin.
Slides were digitalised using a Mirax/Pannoramic automated
slide scanner at a resolution of 230 nm [32]. Further analyses
were performed using the Pannoramic viewer software
(3DHISTECH Ltd., Hungary) and the BZ Analyser software
(Keyence, Germany).
Semi-quantitative Analysis of Immunohistochemistry
To examine differences in microglia response and distribution
as well as quantity of neurons, the partial area covered by
Iba1-positive cells and the number of NeuN-positive cells in
the cortex, respectively, of all mouse strains were determined
by using the Hybrid cell count function of the BZ Analyser
(Keyence, Germany). Therefore, four pictures were taken
from the cortex of each mouse using the Pannoramic viewer
(3DHISTECH Ltd., Hungary) and the ratio of stained cells
area per cortex area was analysed. The mean value was calcu-
lated of at least five mice per mouse strain for both points in
time, 50 and 300 days, respectively.
Behavioural Testing
Rotarod
Locomotor activity of transgenic and control mice was
characterised by the Rotarod performance test. For training,
mice had to walk on a rotating rod (Ugo Basile, Italy) with a
constant speed of 4 rpm for 1 min. After a recovery time of at
least 30 min, they had to perform three trials on an accelerat-
ing (4–32 rpm) rod with a maximum duration of 4 min and an
inter-trial interval of 30min. The time in whichmice fell of the
rod was documented together with the time they first per-
formed passive rotations (without actively walking, but grip-
ping the rod), 240 s were set as cut-off time. Performance of
mice that did not fell of the rod was censored at 240 s; the
proportion of censoring in each mouse model was also deter-
mined. Mice started from an age of 50 days and had to per-
form the test every 4 weeks until reaching the age of 300 days.
At least five mice per mouse strain and time point were
analysed.
Pole Test
To evaluate movement deteriorations and diminished orienta-
tion as characteristics of PD, the pole test was performed.
Therefore, a wooden pole (50 cm height, 0.8 cm diameter)
with a rough surface was placed in the home cage. Cage mates
were removed during this time. The mouse was placed head
upwards near the top of the pole and the time till it turns head
downwards was documented as well as the time it reaches the
floor with all four limbs. Mice were trained three times with a
recovery time of at least 10 min at the first day. At day 2, five
trials were evaluated of which the best trial was used for eval-
uation. Data of mice slipped or fallen of the pole were not
taken into account. Mice started from an age of 50 days and
had to perform the test every 4 weeks until reaching the age of
300 days. At least five mice per strain and time point were
analysed.
Statistics
Statistical analyses of the ELISA, immunohistochemistry and
respirometry data were performed using GraphPad™ prism 6
and one-way ANOVA followed by Sidak’s multiple compar-
ison test, or Kruskal-Wallis test followed by Dunn’s multiple
comparison test if normal distribution was not given, respec-
tively. Significance was reached when p≤0.05.
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Statistical analyses of behavioural tests were performed by
the Institute for Mathematical Stochastics using JMP 9 (SAS
institute, Heidelberg, Germany). Here, we used one-way
ANOVA followed by Bonferroni’s multiple comparison test
for the evaluation of the rate of censoring in the Rotarod data
set. As variance stabilising transformation of data (arcsine-
square root transformation) did not change the outcome of
statistical analysis in this case, we spared and used the raw
data instead. Significance was reached when p<0.05. The Q-
Q plot of the Rotarod data shows that these are distributed
normally until reaching the censoring cut-off time point. Ad-
ditional analyses were performed using R 3.0.2 (R Develop-
ment Core Team, www.r-project.org) and the package ‘lmec’.
This function fits ‘Linear Mixed-Effects Models with Cen-
sored Responses’ as is provided by this data set. Significance
was reached when p<0.05.
Due to a better adjustment to normal distribution, the
‘pole test’ data set was non-parametrically transformed
to mean ranks and fitted to a linear mixed model with
fixed effects for genotype and random effects for ani-
mals. The analyses were performed using the REML
(restricted maximum likelihood) approach and additional
two-sided t test with adjusted degrees of freedom to
determine differences only for the data of main interest,
collected between 25 and 33 weeks of age and addition-
al between 37 and 41 weeks of age. Here again, signif-
icance was reached when p<0.05 (for further informa-
tion, also refer to the methods text in the Supplementary
Material).
Results
Respirometry of C57BL/6J and mtNOD Mice
To analyse functional consequences of the mitochondrial
polymorphisms, we performed respirometric investigations
of functional properties in isolatedmitochondria. Oxygen con-
sumption wasmeasured using four different multiple substrate
protocols (see methods, refer to Supplementary Material
Table 1) to investigate the function of various complexes of
the electron transport chain (ETC) in non-transgenic mice
with mtNOD alterations and compared them with C57BL/6J
controls.
Mean of state- and complex-specific rates of respiration of
at least six experiments for young and old mice are shown in
Fig. 2a, b. In young animals, no significant difference could be
observed between mtNOD and C57BL/6J, respectively, for
complexes I, III and IV related rates of state-specific respira-
tion (refer to Supplementary Material Table 2). However, in
old C57BL/6J animals (200 days) the state 3suc respiration
(complex II) was significantly decreased as compared to
young C57BL/6J mice (100 days), and is also significantly
lower as compared to age-matched old mtNOD mice
(Fig. 2a, b). Since the complex I-dependent rates were not
changed between the different strains, the ratio of complex
I/complex II was higher in old C57BL/6J mice as compared
to mtNODmice as well (Fig. 2a, b). Ratio changes are usually
a sensitive indicator for complex I-dependent impairments if
complex II-respiration is not changed [33]. The substrate-
specific rates of complex I-dependent state 3 rates are shown
in Fig. 2c–e. The results were obtained either by starting the
measurements with glutamate (protocol I) or α-ketoglutarate
(protocol II). No significant changes can be observed in the
respiratory rates of state 3glu/mal (complex I) without added
Ca2+. The extent of the Ca2+ activation of state 3glu/mal (ap-
proximately 163 %) was larger than that of state 3KG/mal (ap-
proximately 134 %) as it is known from earlier measurements
[26], but was not changed due to age or mitochondrial poly-
morphism (refer to Supplementary Material Table 2 for a
Fig. 2 Substrate-specific and respiratory-chain-complex-limited rates as
well as non-phosphorylating rates of respiration of brain mitochondria
isolated from control (C57BL/6J) and mtNOD mice brains. Rates of
respiration as well as ratios were measured as described in ‘Methods’.
The complex II-dependent rates of state 3 respiration in the presence of
glutamate/malate were significantly increased in 200-day-old mtNOD
mice as compared to controls (b; e for detail), and also to young
(100 days) controls (a, number sign indicates significant difference to
200-day-old mitochondria in b). In the presence of α-ketoglutarate
(KG)/malate, the rates of complex II-dependent respiration are clearly
lower as compared to those with glutamate and are not affected by
mtNOD polymorphisms or age (e). No differences are detectable in
other complexes of the electron transport chain (a, b). The rates of state
3glu/mal coefficient are stimulated by Ca
2+ to about 163 % without age- or
polymorphism-related changes (c), whereas the state 3KG/mal coefficient
(d) increased only about 34 %. Nonetheless, the mtNOD polymorphisms
enhanced the Ca2+ activated state 3KG/mal coefficient in 100-day-old
animals significantly by 11 % indicating an increased activity of α-
ketoglutarate dehydrogenase [28]. After Ca2+-addition to the system,
cytosolic Ca2+ activates the mitochondrial glutamate uptake via aralar,
the glutamate aspartate carrier as part of the malate aspartate shuttle.
This mechanism is responsible for pyruvate supply to mitochondria. In
contrast, Ca2+ can after its uptake by mitochondria modulate the activity
intramitochondrial dehydrogenases [57]. Different modes of non-
phosphorylating respiration were determined for complex I- and
complex II-dependent substrates. After inhibition of the adenine
nucleotide carrier with atractyloside, the non-phosphorylating
respiration with succinate as substrate was smaller in old controls
(C57BL/6J) compared old mtNOD mice and to young control mice (f).
The state 4glu/mal/pyr respiration, in the presence of 75 nM adenine
nucleotides (mainly ADP), showed no changes due to age and
polymorphism (g). The rates of non-phosphorylating respiration without
added adenine nucleotides revealed no changes caused by age and
polymorphism (h). Additionally, respiratory control ratios (RCR) were
calculated for complex I-dependent respiration (i) and complex II-
dependent respiration (j). No changes are observable in complex I-
dependent respiration, whereas old control mitochondria show
significantly greater RCRsuc/atractyloside values as compared to young
controls in complex II-dependent respiration (j). Data is presented as
means±SD (n≥11), *, #p≤0.05; **p≤0.01; ***p<0.001 (one-way
ANOVA followed by Sidak’s multiple comparison test and Kruskal-
Wallis test followed by Dunn’s multiple comparison test, respectively)
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summary of the different metabolic states). Whereas, the ab-
solute rates of state 3KG/mal+Ca
2+ were elevated in young
mtNOD animals (Fig. 2d).
Succinate oxidation rates (Fig. 2e) in the presence of glu-
tamate (complex II) were significantly diminished in mito-
chondria of 200-day-old C57BL/6J mice, as described above.
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Interestingly, the rates state 3suc respiration measured with
protocol II in the presence of α-ketoglutarate was generally
smaller than measured with protocol I in the presence of glu-
tamate probably as a result of different levels of the inhibition
by oxaloacetate, as discussed later.
The different protocols allowed us to measure three differ-
ent resting states. The rates of non-phosphorylating respiration
without addition of adenine nucleotides (protocol III; Fig. 2h)
are lower than the rates measured after addition of low
amounts of ADP (state 4, protocol III; Fig. 2g). This is
achieved since the latter rates are partially caused by phos-
phorylation of ADP supplied by extramitochondrial ATPases
that are present in isolated mitochondria (Fig. 2g, h). Only
complex I-dependent substrates contribute to these rates of
respiration, which exhibited no differences caused by mito-
chondrial polymorphisms and/or ageing. The third kind of
resting state was measured with protocol IV after rotenone
and atractyloside addition (Fig. 2f). These rates of respiration
are caused by succinate dehydrogenase (SDH) only.We found
the non-phosphorylating respiration, after rotenone and
atractyloside addition (state 4suc/atractyloside), in 200-day-old
C57BL/6J mitochondria to be decreased when compared to
mitochondria of young C57BL/6J mice (100 days) and to old
mtNOD mice (Fig. 2f). This result reflects similar differences
as measured under state 3 conditions (Fig. 2a, b) and is prob-
ably caused by reduced SDH activity. The quality of coupling
between respiratory chain and phosphorylation is described
by the respiratory control ratio (RCR). The RCR values for
complex I, calculated for the respective state 3 and resting
states, are not changed by age or strain (Fig. 2i). Interestingly,
RCR, calculated from complex II state 3 and state 4 after
atractyloside addition, differs significantly between 100-and
200-day-old C57BL/6J mitochondria (Fig. 2j), confirming
former results. The increasing RCR (state 3suc/state 4suc/
atractyloside) is mainly caused by the decreased state 4suc/
atractyloside respiration. In contrast, there is no significant differ-
ence between the RCR of old C57BL/6 and mtNOD mice but
the rates of state 3suc (+20 %) and state 4suc/cat (+16 %) are
significantly higher in mtNOD compared to C57BL/6 mice.
Biochemical and Immunohistochemical Analyses
Immunohistochemistry
Immunostaining of coronal paraffin-embedded brain sections
of both transgenic mouse models with anti-human aSYN
clone 5G4 revealed an intensive signal in various anatomical
regions of the brain (Fig. 3). In detail, the cortex, thalamus,
hippocampus, basolateral amygdala, geniculate nucleus and
zona incerta were stained most intensive, while the hypothal-
amus, medial amygdala, dentate gyrus and other structures
only show less intense immunolabelling.
The comparison of young and old mice of both strains, tg-
aSYN-B6 and tg-aSYN-mtNOD, showed no differences in
intensity of the signal (not shown). Here, neither an increase
between 50- and 300-day-old tg-aSYNmice, respectivelymice
with mitochondrial DNA polymorphism was found, nor be-
tween both models (see Fig. 3). The enlarged cortex sections
in Fig. 3d, e reveal a slightly more intense staining of 300-day-
old tg-aSYN-B6 compared to tg-aSYN-mtNOD mice. At this
point, the most vigorous labelling can be observed in the neu-
rons of cortical layer V.
Examination of the hippocampus revealed no obvious var-
iances between both mouse models but points out that distinct
regions of the hippocampus show different immunoreactiv-
ities, i.e. missing aSYN expression in the pyramidal cells of
the CA2 region in contrast to a moderate expression pattern in
the CA1 and CA3 regions (see Fig. 3g, h).
To investigate whether immune response and neuronal in-
tegrity are altered in transgenic mice compared with controls,
brain sections were immunostained with specific antibodies.
Figure 4 displays the immunohistochemical analyses of
NeuN, Iba1 and GFAP labelling and a comparison between
young and old tg-aSYN-B6, tg-aSYN-mtNOD and control
mice, respectively. Here, a reduced intensity of NeuN immu-
noreactivity is detectable in old mice (C-H). Iba1 staining
shows only slight visually detectable differences between
age and strains (I-N), whereas GFAP immunostaining sparse
any visible differences and as it is hard to quantify (O-T).
Semi-quantitative Analysis of Immunohistochemistry
For standardised detection of differences in area covered by
neurons and microglial response, we performed semi-
quantitative evaluations. Determination of NeuN-positive area
(neurons) in the cortex of transgenic and control mice shows
no differences between young mice, but revealed significantly
larger neuronal area in the cortex of old C57BL/6J mice as
compared to tg-aSYN-B6 mice. Mice with mtNOD polymor-
phisms show fully rescued neuronal integrity, as the neuronal
area revealed no differences compared to control mice. As
expected, all mouse strains display a significant decline in
neuronal area corresponding to age (Fig. 4a). In contrast, no
differences in microglial response were detected in the cortex
of young mice, and between young and old animals of any
strain. Interestingly, tg-aSYN-mtNOD mice show a signifi-
cantly and tg-aSYN-B6 mice a tendentially increased
microglial response compared to C57BL/6J mice (Fig. 4b).
ELISA
To further evaluate observations made using immunohisto-
chemical analyses, protein was isolated from the brain of mice
and ELISA measurements were performed. Surprisingly, we
found the tg-aSYN-B6 mice to have significantly less
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guanidine-soluble aSYN (aggregates and higher molecular
species) in 300-day-old mice as compared to tg-aSYN-
mtNOD mice. Additionally, the same tendency was visible
for 50-day-old mice (Fig. 5b). In contrast, the carbonate-
soluble aSYN concentration (monomers) showed no differ-
ences between ages and strains (Fig. 5a). The latter may verify
that the production of aSYN(A30P) is driven by the same
promoter activity in both transgenic mouse models.
Behavioural Testing
Rotarod
To determine whether the mitochondrial DNA polymor-
phisms of NOD/J mice have an impact on the motor perfor-
mance of transgenic mice, we performed the Rotarod perfor-
mance test. At least five male mice were analysed in each
Fig. 3 aSYN-immunoreactivity of old tg-aSYN-B6 (b) and old tg-
aSYN-mtNOD mice (c). Sections were immunostained using an anti-
human-aSYN antibody, clone 5G4, and were counterstained for nuclei
with haematoxylin. Localisation of anatomical structure is shown in a
(reduced staining intensity). Intense immunolabelling can be detected in
the neuropil of the cortex (SC), hippocampus (Hc), thalamus (T),
basolateral amygdala (BLP), geniculate nucleus (DLG) and zona incerta
(ZID), whereas staining of hypothalamus (HT), mediale amygdala (BMP,
PMCo) and dentate gyrus (DG) is less intense. aSYN load in the cortex
and hippocampus of 300-day-old tg-aSYN-B6 and tg-aSYN-mtNOD
mice is shown in d–h. The magnified cortex regions (d, e) reveal a
slight difference between old tg-aSYN-B6 (d) and tg-aSYN-mtNOD
mice (e), with tg-aSYN-B6 mice stained more intense. Arrows point to
intensely stained neuronal somata. The most vigorous staining can be
observed in cortical layer V (d,e). In comparison to tg-aSYN-B6 (g)
and tg-aSYN-mtNOD mice (h), no staining is detectable in the
hippocampus of controls (f). The pyramidal cells show the most intense
staining in the CA1 and CA3 regions whereas the CA2 region sparse any
labelling and is aSYN-negative (g, h). RSD retrosplenial dysgranular
cortex, Hc hippocampus, MPT medial pretectal nucleus, SC
somatosensory cortex, CA cornu ammonis, DLG dorsal lateral
geniculate nucleus, T thalamus, ZID zona incerta, dorsal part, fr
fasciculus retroflexus, cp cerebral peduncle, LV lateral ventricle, BLP
basolateral amygdaloid nucleus, posterior part, BMP basomedial
amygdaloid nucleus, posterior part, DG dentate gyrus, HT
hypothalamus, PMCo posteromedial cortical amygdaloid area; Scale
bar=1000 μm in a–c; 100 μm in d, e; 500 μm in f–h
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group, i.e. tg-aSYN-B6, tg-aSYN-mtNOD and C57BL/6J
(control) mice. According to the cut-off time of 240 s, first
analyses were conducted with respect to the percentage of
censoring. The results reveal a significantly higher amount
Fig. 4 Immunohistochemical
analyses of young and old tg-
aSYN-B6, tg-aSYN-mtNOD and
C56BL/6 control mice (Ctrl).
Semi-quantitative analysis of
immunolabelling reveals
significant differences in neuron
integrity between young and old
mice and especially between old
tg-aSYN-B6 and old control mice
(a). Examination of microglial
response shows a significant
difference between 300-day-old
tg-aSYN-mtNOD and 300-day-
old control mice (b). Young tg-
aSYN-B6 (c) and tg-aSYN-
mtNOD (e) mice show a more
intensive NeuN-staining as
compared with old mice (d and
g); old tg-aSYN-B6 mice also
reveal less neurons in cortical
layer V. There are hardly any
changes visible in the GFAP
labelling (o–t), whereas Iba1
labelling shows slightly stronger
microglial activity in old
transgenic mice (j, l) compared
with C57BL/6J control mice (n).
Scale bar=100 μm in c–t. Data is
presented as means±SD (n≥5),
*p≤0.05; **p≤0.01; ***p<0.001
(one-way ANOVA followed by
Sidak’s multiple comparison test)
Fig. 5 Quantification of aSYN in the brains of tg-aSYN-B6 and tg-
aSYN-mtNOD mice. The carbonate-soluble aSYN levels show no
differences in young and old mice and between the mouse models (a),
whereas mice with mitochondrial polymorphism show significantly higher
amounts of guanidine-soluble aSYN at 300 days of age when compared to
tg-aSYN-B6mice (b). Note the unchanged amount of total aSYN between
both time points. Data is presented as means±SD (n≥6), *p≤0.05 (one-
way ANOVA followed by Sidak’s multiple comparison test)
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of censored data in case of tg-aSYN-mtNOD mice (75 %) as
compared to tg-aSYN-B6 mice (34 %) and control mice
(23 %), calculated for the points in time in which the greatest
differences were expected, i.e. 25–33 weeks (not shown). Due
to the large portion of censoring (mice reaching 240 s), further
statistical analyses required a better-fitted model.
To verify the influence of the mitochondrial polymor-
phisms on the rotarod performance during the defined periods
(9–41 weeks), a linear statistical model was adjusted to the
obtained data set. This model was used to compare tg-aSYN-
B6 and tg-aSYN-mtNOD mice, and tg-aSYN-B6 and ctrl
mice, respectively.
Given the fact that each mouse was measured at several
time points, it was recommended to fit these repeated mea-
surements using precisely a ‘linear mixed model with random
effects’. However, the great proportion of censoring in each
mouse model led to requirement of an additional adjustment
to this statistic model. Performing Linear Mixed-Effects
Models with Censored Responses (LMEC), we were able to
statistically verify that tg-aSYN-mtNOD mice perform signif-
icantly better as compared to tg-aSYN-B6 mice in both de-
fined parameters, i.e. maximum latency on the rod and time
until first passive rotation (p=0.0158, p=0.0318) in the exam-
ined time period. However, highest differences (p<0.0002)
were found at mid-age time points between 25 and 33 weeks
of age for both, time until first passive rotation and maximum
latency on the rod (Fig. 6). No changes in motor performances
were found between tg-aSYN-B6 and control mice, indicating
missing phenotypic alterations in the transgene mouse models
(Fig. 6). The linear influence of age was calculated for the
rotarod performance to control for age-related effects in the
mouse models.
As an effect of training was statistically excluded, it was
most interesting to detect that age has a comparable strong
influence on the rotarod performance (p<0.04), as C57BL/
6J, tg-aSYN-B6 and tg-aSYN-mtNOD mice, respectively,
were able to improve their performance with advancing age
(for further information of the statistical analyses, please refer
to the text in the Supplementary Material).
Pole Test
To evaluate parameters of dementia and motoric alteration, the
pole test was chosen. Here, the mice need good spatial orien-
tation and high motoric skills to turn 180° and climb head
downwards to the ground. The best of all five trials was taken
for further evaluation. Data of mice, which slipped or felt off
or performed only parts of the pole, were not used for analysis.
Here, again a linear mixed model was fitted to statistically
analyse the collected data over the described periods in time,
25–33 weeks (mid-age) and 37–41 weeks (old age), respec-
tively. Interestingly, analyses of mid-age points in time (25–
33 weeks) displayed no significant changes in both deter-
mined parameters (climb latency and time-until-turn-latency)
(p≥0.06). Here, only a tendency of different climb perfor-
mance was detectable, as tg-aSYN-mtNOD mice seemed to
improve their performance as compared to tg-aSYN-B6 and
C57BL/6J mice.
However, we found mice at older age (37–41 weeks) to
show more distinct differences, especially a significantly bet-
ter orientation performances (time-until-turn-latency) in tg-
aSYN-mtNOD mice (p=0.0237) (Fig. 7a), and surprisingly
a decreased climbing performance in C57BL/6J mice
(p=0.001) as compared tg-aSYN-B6 mice (Fig. 7b).
Fig. 6 Age-dependent alteration in motor behaviour of tg-aSYN-B6, tg-
aSYN-mtNOD and control mice (C57BL/6J). Latency of rotarod
performances (a) and time until first passive rotation (b) of tg-aSYN-B6
mice and controls show no differences until the age of 41 weeks (end
date), whereas tg-aSYN-B6 and tg-aSYN-mtNOD mice differ
significantly along the time points, with the most significant differences
between 25 and 33 weeks of age. The evaluation of censored data reveals
a significantly greater amount of censoring (reaching the cut-off time of
240 s) in case of tg-aSYN-mtNOD mice as compared to tg-aSYN-B6
mice and control mice (not shown). Data is presented as means±SD
(n≥5, male) (LMEC, for further information, see text in Supplementary
Material)
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Discussion
Mitochondrial dysfunction is one of the major hypotheses
describing a causative role for PD. It is thought that during
age, mutations in the mitochondrial genome (mtDNA) accu-
mulate and lead to the excessive production of reactive oxy-
gen species (ROS). ROS are implicated in a wide range of
neurodegenerative diseases as they are thought to enhance
the propensity of peptides to aggregate, e.g.β-amyloid, aSYN
[17, 34, 35]. Evidence for the assumption of mutations in the
mitochondrial genome being implicated in ageing were first
brought using a knock-in mouse model with a mutated
mtDNA-polymerase A [36]. A decreased lifespan and early
onset of age-related phenotypes were described due to a defi-
ciency in the proof-reading function of the protein [37]. Ad-
ditionally, first hints were collected when complex I-
deficiency in cells of the substantia nigra pars compacta was
discovered in patients with Parkinson’s disease (reviewed in
[5, 38]).
In the reported study, we analysed two genetically different
tg-aSYN mouse strains expressing human aSYN with the
‘A30P’ mutation. The first one, the tg-aSYN-B6 strain, is a
well-known and characterised model for cortical α-
synucleinopathies [24]. The second strain, related from ‘non-
obese diabetic’ (NOD) mice, has additional mitochondrial
DNA polymorphisms (tg-aSYN-mtNOD). Mice with these
variations were already investigated in the context of
Alzheimer’s disease and formerly described to reveal a higher
production of ATP [23]. As they are widely used in other
fields of research, too, they are well characterised and have
been sequenced previously [25]. Table 1 shows an overview
of gene and amino acids changes of NOD/LtJ mice as com-
pared to C57BL/6J mice.
We compared both transgenic mouse strains (tg-aSYN-B6
and tg-aSYN-mtNOD) with the C57BL/6J controls regarding
aSYN load, immune response, neuron integrity and behav-
ioural changes with the focus on differences due to mitochon-
drial polymorphisms. Although tg-aSYN-B6 mice tend to de-
velop epileptic seizures with advancing age, we did not find
phenotypic alterations as compared to control mice in the first
place. The same holds true for tg-aSYN-mtNOD mice, which
do not show any differences when compared to tg-aSYN-B6
and C57BL/6J mice.
Immunohistological analyses revealed a slightly more in-
tensive immunolabelling with anti-human aSYN antibody
(clone 5G4) in the brains of tg-aSYN-B6 than in tg-aSYN-
mtNODmice, indicating a higher aSYN burden. In contrast to
findings of Kovacs et al. [39], who described no background
or synaptic staining in brain sections of PD patients but strong
labelling of intracellular and neuritic structures using this an-
tibody and a slightly different tissue preparation, we observed
a strong background staining in bothmouse models.We found
the synapses and somata in the brains neurons to be strongly
labelled, probably because the artificial overexpression of hu-
man aSYN ‘A30P’ leads to the formation of mainly small
oligomers enriched in synapses and somata rather than aggre-
gates and fibrils which are the preferred targets of this anti-
body [39, 40]. In addition to this, it was described before that
the overexpression of aSYN in mouse models does not lead to
the formation of Lewy bodies-like in human brain tissue
Fig. 7 Changes in pole test performances of tg-aSYN-B6, tg-aSYN-
mtNOD and C57BL/6J control mice. No significant alterations were
detected in time-until-turn-latency (a) and climb latency (b) until old
age. A better orientation performance (time-until-turn-latency) was
found in tg-aSYN-mtNOD mice at older age, i.e. 37–41 weeks (a). At
the same points in time, the climb latency surprisingly revealed reduced
performance of control mice when compared to tg-aSYN-B6 mice (b).
Data is presented as means±SEM (n≥5, male). (restricted maximum
likelihood (REML) approach and additional two-sided t test with
adjusted degrees of freedom)
Table 1 Mitochondria gene differences between NOD/LtJ and C57BL/
6J mice (adopted from [25])
Gene mtDNA position C57BL/6J NOD/LtJ Amino acids
Cox3 9348 bp G A Val > Ile
ND3 9461 bp C T Met > Met
tRNAArg 9821 bp 8A repeats 10A repeats
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(reviewed in [41]). As expected, anatomical structures were
strongly stained including those implicated inmemory, behav-
iour and motoric skills like the hippocampus, amygdala,
somatosensoric cortex and thalamus. Here, no differences in
intensity could be determined between young and old tg-
aSYN-B6 and tg-aSYN-mtNOD mice, respectively (not
shown). Furthermore, only little differences between old tg-
aSYN-B6 and tg-aSYN-mtNOD mice were detectable,
whereby old tg-aSYN-B6 display a slightly more intense
staining in the cortex, leading to the impression that the aSYN
load is greater in tg-aSYN-B6 mice. Due to the expression
pattern of the Thy1-promoter, several structures sparse any
immunolabelling including substantia nigra and the olfactory
bulb, both prominently affected in post mortem brain tissue of
PD patients, but were described earlier to lack aSYN in trans-
genic PD mouse models [42]. C57BL/6J mice show no im-
munoreactivity at all. The strong, almost ubiquitous staining
complicates a definite statement of differences in aSYN load
and distribution between both transgenic mouse models.
To define differences in aSYN burden, we performed
ELISA measurements. Surprisingly, we found the tg-aSYN-
mtNOD mice to have significantly increased guanidine-
soluble aSYN (higher molecular species) in the brain as com-
pared to tg-aSYN-B6 mice. Unexpectedly, we did not observe
any difference in the amount of carbonate-soluble (monomers
and small oligomers) aSYN in the brain between tg-aSYN-B6
and tg-aSYN-mtNODmice, neither at 50 days nor at 300 days
of age. Noticeably, an increase in aSYN concentration (mono-
mers/small oligomers and higher molecular species) with ad-
vancing age in the brains of both transgenic mouse models
was missing, instead a tendency to decreased aSYNmeasured
in the brain of 300-day-old mice compared to 50-day-old ones
could be revealed. Together with the aforementioned missing
increase in aSYN staining in young and old tg-aSYN and tg-
aSYN-mtNOD mice, it became thinkable that mechanisms
exist which remove aSYN continuously from the brain and
lead to an equilibrium between production and removal,
resulting in the observed steady state of aSYN burden in the
brain of young and old tg-aSYN and tg-aSYN-mtNOD mice,
respectively.
In this context, the combined finding of old tg-aSYN-
mtNOD having an increased immune response (Iba1) as com-
pared to controls and the neuronal integrity in aged tg-aSYN-
mtNOD mice being rescued to levels of age-matched C57BL/
6Jmice is most interesting. Although the number of neurons is
drastically reduced in all strains, indicating that the degenera-
tion process is part of the normal ageing, the neuronal area of
old tg-aSYN-B6 mice is reduced by further 35 % compared to
age-matched control mice. A conceivable cause for the neu-
ronal degradation is the impaired aSYN functionality and the
resulting loss of function as modulator of synaptic activity. As
aSYN binds to synaptic vesicles and serves as part of the
SNARE-complex [43], it is most likely that alteration leads
to neuronal degradation as common mechanism. Burré et al.
[44] recently showed that the ‘A30P’ mutation is unique
among the aSYN point mutations in impairing SNARE-
complex formation.
Taken together, these findings emphasises the supposition
of higher molecular forms of aSYN being less toxic than the
smaller soluble moieties, and the aggregation to be a mecha-
nism that mediates protection of neurons from further damage.
This observation gets well along with proposals made by sev-
eral other research groups and in the context of different neu-
rodegenerative diseases [45–47].
These findings further support the theory of a neuroprotec-
tive effect emanating from microglia, a topic which has been
controversially discussed (reviewed in [48]) especially in the
context of mitochondrial influence in neurodegeneration [49].
To verify, if the described changes in tg-aSYN-mtNOD
mice are not only histological phenomena but have indeed a
beneficial impact on motor skills, behavioural tests were per-
formed. Firstly, tg-aSYN-B6 mouse models display age-
dependent movement abnormalities as previously described
[50]. Freichel et al. [42] found old tg-aSYN-B6 mice to be
significantly worse in the fear conditioning and active avoid-
ance tests, in which the involvement of the amygdala and
hippocampus is required. Interestingly, these mice show a
worsening in the Rotarod performance test, but starting not
earlier than 12months of age. As we were mainly interested in
earlier time points, we concentrated on the age of 50 to
300 days and could verify no differences between tg-aSYN-
B6 and control mice as well. The cut-off time of 240 s in the
Rotarod performance procedure provides some difficulties in
the statistical analysis, but gave interesting results on its own.
The rate of censoring, i.e. of reaching the highest possible time
on the rod without falling off, differs tremendously between
transgenic mice. As expected, tg-aSYN-mtNODmice achieved
significantly better results possibly due to their intact neuronal
integrity.
Intriguingly, we found tg-aSYN-mtNOD mice to perform
significantly better in the Rotarod performance test as com-
pared to tg-aSYN-B6, with the most tremendous differences at
mid-age points in time (25–33 weeks).
Furthermore, we propose that age plays a significant role in
this process. Surprisingly, both mouse models, tg-aSYN-B6
and tg-aSYN-mtNOD, show a positive increase in their per-
formance with advancing age, with the highest increase for tg-
aSYN-mtNOD mice. These results further confirm the notion
of tg-aSYN-mtNOD mice to have a great benefit from the
effects elicited by their mitochondrial polymorphisms.
The pole test could reveal similar results. The tg-aSYN-B6
mice show a significantly decreased time-until-turn perfor-
mance at old age (37–41 weeks) as compared to tg-aSYN-
mtNOD mice. The latter show a stable level of performance.
The time the mice needed to climb down the wooden pole to
reach the floor varies strongly among the age groups.
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Statistical significance was only reached for the increased per-
formance of C57BL/6J mice.
The Rotarod and pole test are methods to examine
coordinated motor skills and are widely used to detect
nigrostriatal damage and dopaminergic denervation
[51–53]. The missing difference between our tg-aSYN-
B6 mouse model and the C57BL/6J (Ctrl) mice is
founded in the lack of SNpc pathology due to the ex-
pression pattern of the Thy1 promoter, described before
[50, 54]. The tg-aSYN-B6 mouse was therefore found to
be not suitable to model purely motor disease aspects of
PD, but useful to reproduce extranigral facets of PD and
additionally dementia with Lewy bodies [50, 54].
The strong difference between tg-aSYN-B6 and tg-aSYN-
mtNODmice in the rotarod performance but missing variance
in the climb performance of the pole test can be explained by
the less phenotypic alteration in the transgenic mice. This very
sensitive pole test [51] is most likely not suitable for
extranigral aspect determination and stronger incentives for
the mice are needed for future analyses. However, the ability
of spatial orientation, a non-motor task, as part of the Pole test
was disturbed in old tg-aSYN-B6 and control C57BL/6Jmice,
and was increased in tg-aSYN-mtNOD mice. Thus, a strong
positive effect on the motor performance and spatial orienta-
tion task was found in tg-aSYN-mtNODmice, confirming the
described results.
To evaluate the influence of mitochondrial polymorphisms,
we investigated brain mitochondria isolated from mice, by
means of high-resolution respirometry with substrate inhibitor
titrations [55, 56]. To obtain a maximum of information, we
developed a new set of four protocols on the basis of
longstanding experiences and the discovery of new functional
properties of brain mitochondria [26, 28, 33, 55, 57–59]. This
allowed the precise determination of (i) maximal substrate
specific rates of state 3 respiration, (ii) maximal rates limited
by the capacity of the respiratory chain complexes, (iii) respi-
ratory control ratios, (iv) substrate specific Ca2+ stimulation of
state 3 respiration and (v) resting rates of respiration under
three different conditions. Interestingly, we mainly detected
differences in succinate-dependent parameters of the mito-
chondrial function in old animals: (i) the rate of state 3suc
respiration was about 20 % lower in 200-day-old control mice
than in the presence of NOD mitochondria and lower in both
groups of young mice (C57BL/6J and mtNOD mice, respec-
tively). (ii) For the same reason, the ratio of complex I/com-
plex II-limited respiration was increased by 15% in C57BL/6J
(control) mice as compared to old mtNOD mice. (iii) More-
over, the rates of state 4complex II respiration were also lower in
brain mitochondria from 200-day-old C57BL/6J (control)
mice whereas the rates of state 4complex I respiration were not
changed in any of the groups. The repeated findings of dimin-
ished succinate respiration in C57BL/6J mice using four dif-
ferent protocols (and starting parameters) indicates that there
are indeed metabolic conditions causing reduced succinate-
dependent rates of respiration which do not occur in the
mtNOD mice.
What could be the reason for the diminished fluxes through
complex II?
It is known that the activity of SDH, which oxidises
succinate-forming fumarate, is dependent on the concentra-
tion of oxaloacetate and malate, both inhibitors of SDH [60].
This mechanism can explain why the succinate respiration as
measured with α-ketoglutarate/malate (protocol II) was at
least 40 % lower than measured with glutamate/malate in pro-
tocol I (Fig. 2). It is probably caused by different concentra-
tions of oxaloacetate in both kinds of incubation. The mito-
chondrial aspartate amino-transaminase (ASAT) catalysing
the reaction (glutamate + oxaloacetate = α-ketoglutarate +
aspartate) can work in two directions: either decreasing the
oxaloactetate concentration if reacting with glutamate or
forming oxaloacetate if reacting with α-ketoglutarate. There-
fore, using the glutamate containing incubation protocol, the
oxaloacetate concentration is lowest and not inhibiting SDH,
whereas in the presence of α-ketoglutarate, oxaloacetate it is
at maximum, partially inhibiting SDH. If this explanation is
correct, the reduced rates of succinate respiration found for old
C57BL/6J mice in the glutamate containing protocol I
(Fig. 2e) cannot be caused by an increased oxaloacetate con-
centration. Therefore, we assume that this effect could be
caused by a diminished activity of SDH or the electron-
transferring flavoprotein-ubichinone oxidoreductase (ETF),
possibly caused by increased oxidative stress. In the old
mtNOD animals, the rate of non-phosphorylating respiration
with succinate is higher than in the controls. This could cause
a reduced ROS formation under conditions where the SDH or
the electron-transferring flavoprotein-ubichinone oxidoreduc-
tase (ETF) is especially required. Although succinate is not an
important substrate for feeding the brain’s mitochondria, suc-
cinate is an important metabolite of the citrate cycle, and any
limitation in its oxidation capacity can limit the oxidation
capacity of the citrate cycle and limit the supply of reducing
equivalents to the respiratory chain.
Even if there is no explanation for this interesting phenom-
enon today, there is no doubt that these findings reveal addi-
tional insights into the network of mitochondria and neurode-
generative diseases.
Taken together, we can infer that altered complex II-
respiration potentially accompanied by an increased ATP pro-
duction caused by mitochondrial polymorphisms occurs to-
gether with and may be responsible for improvement of mo-
toric function and neuron integrity in tg-aSYN-mtNOD mice
over a specific period of time, indicating disturbed ATP-
dependent mechanisms like peptide degradation/removal and
impaired SNARE-complex formation in the first place and
again emphasising the important role of mitochondria in neu-
rodegenerative diseases. This is conceivable as the brain is the
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largest consumer of energy in the body and it maintains its
metabolism at equilibrium states.
A disturbed balance between influx and efflux of various
substances and metabolites between blood and brain as pro-
vided by the transport via ATP-binding cassette transporter
(ABC transporter) is crucial for the development of patholog-
ical conditions (reviewed in [61]). For example, the known
ABCB10 transporter was recently identified to contribute to
the prevention of oxidative stress by the export of yet un-
known peptides in the inner mitochondrial membrane
(reviewed in [62]). A decreased activity might additionally
lead to mitochondrial dysfunction. Evidence was furthermore
given by several studies for ABC transporter activity to be
decreased in neurodegenerative diseases [29, 63]. This de-
creased activity is thought to lead to diminished detoxification
of disease-associated regions in the brain, e.g. substantia nigra
in Parkinson’s disease, hippocampus/temporal cortex in
Alzheimer’s disease and caudate nucleus in Huntington’s
disease [64].
In conclusion, alterations in the mitochondrial genomemay
pose benefits for the physiological fitness of mice overex-
pressing aSYN as seen in the Rotarod performance test and
for the neuronal integrity as evidenced by immunohistochem-
istry. Thus, pharmacological intervention in mitochondrial
function should be further examined in order to develop new
strategies for disease modifying therapies.
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